

# Patrick Forde

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9680956/patrick-forde-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

56  
papers

4,019  
citations

30  
h-index

63  
g-index

70  
ext. papers

6,158  
ext. citations

11  
avg, IF

5.07  
L-index

#	Paper	IF	Citations
56	Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.. <i>BMJ Open</i> , <b>2022</b> , 12, e057663	3	3
55	Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC.. <i>Cancer Treatment Reviews</i> , <b>2022</b> , 104, 102350	14.4	2
54	Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors.. <i>Cancer Immunology, Immunotherapy</i> , <b>2022</b> , 1	7.4	0
53	Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.. <i>Npj Precision Oncology</i> , <b>2022</b> , 6, 13	9.8	1
52	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.. <i>New England Journal of Medicine</i> , <b>2022</b> ,	59.2	59
51	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma <b>2022</b> , 10, e003956		0
50	Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. <i>Nature Medicine</i> , <b>2021</b> , 27, 1910-1920	50.5	14
49	Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy. <i>Lung Cancer</i> , <b>2021</b> , 154, 36-43	5.9	6
48	Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spatalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3620-3629 <sup>18</sup>	12.9	18
47	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. <i>Nature</i> , <b>2021</b> , 596, 126-132	50.4	40
46	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers <b>2021</b> , 9,		6
45	Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies. <i>Oncologist</i> , <b>2021</b> , 26, e1822-e1832	5.7	4
44	Detection and characterization of lung cancer using cell-free DNA fragmentomes. <i>Nature Communications</i> , <b>2021</b> , 12, 5060	17.4	21
43	Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	2
42	Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC. <i>JTO Clinical and Research Reports</i> , <b>2021</b> , 2, 100220	1.4	0
41	PD-1 Blockade in Anaplastic Thyroid Carcinoma. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2620-2627	2.2	76
40	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 914-947	8.9	71

39	Epigenetic therapy inhibits metastases by disrupting premetastatic niches. <i>Nature</i> , <b>2020</b> , 579, 284-290	50.4	109
38	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 332-338	2.4	81
37	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1327-1337	12.9	46
36	Moving Immunotherapy Into Early-Stage Lung Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , <b>2020</b> , 26, 543-547	2.2	4
35	Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. <i>Nature Cancer</i> , <b>2020</b> , 1, 99-111	15.4	67
34	Consolidative Radiotherapy in Oligometastatic Lung Cancer: Patient Selection With a Prediction Nomogram. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, e622-e632	4.9	6
33	Isolated progression of metastatic lung cancer: Clinical outcomes associated with definitive radiotherapy. <i>Cancer</i> , <b>2020</b> , 126, 4572-4583	6.4	4
32	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer <b>2020</b> , 8,		40
31	Immunotherapy for mesothelioma: rationale and new approaches. <i>Clinical Advances in Hematology and Oncology</i> , <b>2020</b> , 18, 562-572	0.6	4
30	Genome-wide cell-free DNA fragmentation in patients with cancer. <i>Nature</i> , <b>2019</b> , 570, 385-389	50.4	339
29	Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, e470-e479	4.9	42
28	Immunotherapy trials in mesothelioma - promising results, but don't stop here. <i>Nature Reviews Clinical Oncology</i> , <b>2019</b> , 16, 726-728	19.4	5
27	The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 4305-4315	15.9	47
26	Use of Immune Checkpoint Inhibitors in Mesothelioma. <i>Current Treatment Options in Oncology</i> , <b>2019</b> , 20, 18	5.4	39
25	Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 494-502	8.9	64
24	Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , <b>2019</b> , 79, 1204-1213	10.1	50
23	PD-1 Blockade in Early-Stage Lung Cancer. <i>Annual Review of Medicine</i> , <b>2019</b> , 70, 425-435	17.4	15
22	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , <b>2019</b> , 79, 1214-1225	10.1	117

21	A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. <i>Oncologist</i> , <b>2018</b> , 23, 859-865	5.7	45
20	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1976-1986	59.2	865
19	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 100, 916-925	4	162
18	Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 48, 553-557	5.3	89
17	Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). <i>Annals of Oncology</i> , <b>2018</b> , 29, 1853-1860	10.3	153
16	Lung and Thymic Carcinoids. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2018</b> , 47, 699-709	5.5	5
15	The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. <i>Cancer Immunology Research</i> , <b>2018</b> , 6, 888-899	12.5	60
14	Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1930-1939	8.9	160
13	Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series <b>2018</b> , 6, 104		35
12	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. <i>Oncologist</i> , <b>2017</b> , 22, 627-630	5.7	49
11	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , <b>2017</b> , 7, 264-276	24.4	491
10	Clinical mutational profiling of 1006 lung cancers by next generation sequencing. <i>Oncotarget</i> , <b>2017</b> , 8, 96684-96696	3.3	27
9	Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 45237-45248	3.3	22
8	Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1493-502	8.9	177
7	Professional and ethical responsibilities in adverse events and medical errors: discussions when things go wrong <b>2015</b> , 145-157		
6	Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 414-8	8.9	23
5	HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 314-8	4.7	81
4	Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 673-84	8.9	18

- 3 The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy). *Blood*, **2013**, 122, 4629-4629 2.2 1
- 2 Venous Thromboembolism Prevention Practices Among Health Care Providers Caring for Patients Hospitalized for Hematopoietic Stem Cell Transplantation: A International Web-Based Survey. *Blood*, **2012**, 120, 2062-2062 2.2
- 1 Ipilimumab-induced immune-related renal failure--a case report. *Anticancer Research*, **2012**, 32, 4607-8 2.3 41